Clinical trials: Primary Peritoneal Cancer
Ovarian Cancer
Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Ovarian Cancer
Phase IIA, multicenter, dose escalation study evaluating the safety and efficacy of weekly S-8184 paclitaxel injectable emulsion in second line treatment of patients with stage III or IV platinum resistant ovarian cancer or…
- Trial name
- NCT00034151
- Testing
- S-8184 Paclitaxel Injectable Emulsion
- Volunteers
- 52 people
- Sponsor
- Achieve Life Sciences
Platinum-sensitive Relapsed Epithelial Ovarian Cancer, Platinum-sensitive Relapsed Fallopian Tube Cancer
Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer
The purpose of this study is to measure the efficacy and safety of torvutatug samrotecan (torvu-sam) with or without bevacizumab compared to standard of care (SoC) as maintenance treatment in participants with platinum-sensitive…
- Conditions
- Platinum-sensitive Relapsed Epithelial Ovarian Cancer, Platinum-sensitive Relapsed Fallopian Tube Cancer, Platinum-sensitive Relapsed Primary Peritoneal Cancer
- Trial name
- TREVI-OC-03 (NCT07816666)
- Testing
- Torvutatug samrotecan, Bevacizumab
- Where
- 124 sites in United States, Australia and 11 more
- Volunteers
- 600 people
- Sponsor
- AstraZeneca
Triple Negative Breast Cancer, Non-small Cell Lung Cancer
A Biomarker Screening Protocol for Participants With Solid Tumors
Biomarker Screening Protocol for Preliminary Eligibility Determination for Adoptive T-cell Therapy Trials:This is a decentralized, multi-site, US-based biomarker screening study to identify participants who have specific disease…
- Conditions
- Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic
- Trial name
- START (NCT05891197)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Lyell Immunopharma, Inc.
Ovarian Tumors
First-in-Human Evaluation of GRN-300 in Subjects With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers.
The study consists of two parts based on the administration of single-agent GRN-300 or in combination with paclitaxel. Part 1 (Phase IA) will test the tolerability of continuous twice a day dosing of oral GRN-300, a…
- Trial name
- NCT04711161
- Testing
- GRN-300, Paclitaxel
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- Green3Bio, Inc.
Ovarian Cancer, Epithelial Ovarian Cancer
A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)
The purpose of this study is to determine which patients with ovarian, fallopian tube, and primary peritoneal cancer will best respond to treatment with rucaparib.
- Conditions
- Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- ARIEL2 (NCT01891344)
- Testing
- Oral rucaparib
- Where
- 75 sites in United States, Australia and 4 more
- Volunteers
- 491 people
- Sponsor
- pharmaand GmbH
Ovarian Epithelial Cancer, Fallopian Tube Cancer
p53 Gene in Treatment of Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
The study objective is to investigate the efficacy and safety of p53 combined with chemotherapy (cisplatin and paclitaxel) in treatment of recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer.
- Conditions
- Ovarian Epithelial Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT02435186
- Testing
- p53 gene, Cisplatin, Paclitaxel
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shenzhen SiBiono GeneTech Co.,Ltd
Ovarian Neoplasms, Peritoneal Neoplasms
BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer
This phase I, open label dose escalation study will investigate the addition of BIBF 1120 to treatment with the combination of carboplatin and Pegylated Liposomal Doxorubicin (PLD) in patients with advanced, platinum sensitive…
- Trial name
- NCT01314105
- Testing
- BIBF 1120 + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min, BIBF 1120+ PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min
- Where
- 3 sites in Spain
- Volunteers
- 19 people
- Sponsor
- Boehringer Ingelheim
Neoplasms, Ovarian
A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
The purpose of the study is to assess the safety, tolerability, and efficacy of farletuzumab ecteribulin (MORAb-202) and compare it to Investigator's choice (IC) chemotherapy in female participants with platinum-resistant HGS…
- Trial name
- NCT05613088
- Testing
- MORAb-202, Paclitaxel, Pegylated Liposomal Doxorubicin (PLD)
- Where
- 50 sites in United States, Australia and 7 more
- Volunteers
- 106 people
- Sponsor
- Bristol-Myers Squibb
Ovarian Cancer, Peritoneal Neoplasms
A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer
To evaluate the efficacy of voloxicimab when administered at 15 mg/kg qwk in subjects with platinum-resistant, advanced epithelial ovarian cancer or primary peritoneal cancer.
- Trial name
- NCT00516841
- Testing
- Volociximab
- Where
- 23 sites in United States, Canada
- Volunteers
- 16 people
- Sponsor
- Facet Biotech
Epithelial Ovarian Cancer, Fallopian Tube Cancer
Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)
This is a randomized, open label, multicenter trial to evaluate the safety, dosing, efficacy and biological activity of intraperitoneal IMNN-001 plus NACT compared to NACT alone.
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- OVATION 2 (NCT03393884)
- Testing
- IMNN-001, Carboplatin, Paclitaxel
- Where
- 21 sites in United States, Canada
- Volunteers
- 130 people
- Sponsor
- Imunon
Epithelial Ovarian Cancer, Fallopian Tube Cancer
Efficacy and Safety of BG-C9074 With Bevacizumab Compared With Bevacizumab in Adults With Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
The purpose of this study is to evaluate the safety and efficacy of BG-C9074 with bevacizumab (Arm A) versus bevacizumab monotherapy (Arm B) in adults with epithelial ovarian, fallopian tube, or primary peritoneal cancers who…
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT07811271
- Testing
- BG-C9074, Bevacizumab
- Volunteers
- 600 people
- Sponsor
- BeOne Medicines
Ovarian Cancer
A Phase III Study of BD0801 Combined With Chemotherapy in Recurrent, Platinum-resistant Epithelial Ovarian Cancer
The standard systemic treatment for ovarian cancer is platinum-based chemotherapy. However, majority of patients relapse and eventually progress to platinum resistance.
- Trial name
- NCT04908787
- Testing
- BD0801, Paclitaxel, Topotecan
- Where
- 55 sites in China
- Volunteers
- 421 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Low-grade Serous Ovarian Cancer, Low-grade Serous Fallopian Tube Cancer
A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer
The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer) is a Phase 3 study during which patients with recurrent or persistent low-grade serous (LGS) carcinomas of the ovary, fallopian tube or primary peritoneum will…
- Conditions
- Low-grade Serous Ovarian Cancer, Low-grade Serous Fallopian Tube Cancer, Low-grade Serous Peritoneal Cancer
- Trial name
- NCT01849874
- Testing
- MEK162, MEK inhibitor; oral, Physician's choice chemotherapy
- Where
- 226 sites in United States, Australia and 17 more
- Volunteers
- 341 people
- Sponsor
- Pfizer
Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
The primary purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of GTAEXS617 (REC-617) in participants with advanced solid tumors.
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC)
- Trial name
- ELUCIDATE (NCT05985655)
- Testing
- GTAEXS617, SoC
- Where
- 15 sites in United States, Belgium and 1 more
- Volunteers
- 230 people
- Sponsor
- Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.